Cancer

Patient sample, cell culture and mouse studies suggest bispecific antibodies targeting CD3 and either BCMA or FCRL5 could help treat multiple myeloma (MM). In MM cells from patients and human MM cell lines, an anti-CD3/BCMA (EM801) or an anti-CD3/FCRL5 bispecific antibody increased apoptosis compared with a control bispecific antibody or vehicle. In a xenograft mouse model of MM, the antibodies decreased tumor growth. Next steps by the Genentech Inc. unit of Roche include additional, undisclosed preclinical testing of the anti-CD3/FCRL5 bispecific antibody...